Abdalla, HI, Ahmoye, NM, Brinsden, P et al. (1987). The effect of the dose of human chorionic gonadotrophin and the type of gonadotrophin stimulation on oocyte recovery rates in an in-vitro fertilization program. Fertil Steril 48:958–63.CrossRefGoogle Scholar

Abdel Gadir, A, Khatim, MS, Mowafi, RS et al. (1990a). Hormonal changes in patients with polycystic ovarian disease after ovarian electrocautery or pituitary desensitization. Clin Endocrinol 32:749–54.CrossRefGoogle Scholar

Abdel Gadir, A, Mowafi, RS, Alnaser, HM et al. (1990b). Ovarian electrocautery, human menopausal gonadotropins and pure follicle stimulating gormone therapy in the treatment of patients with polycystic ovary disease. Clin Endocrinol (Oxford) 33:585–92.CrossRefGoogle Scholar

Abdul-Jalil, AK, Child, TJ, Phillips, S et al. (2001). Ongoing twin pregnancy after ICSI of PESA-retrieved spermatozoa into in-vitro matured oocytes: case report. Hum Reprod 16:1424–6.CrossRefGoogle ScholarPubMed

Aboulghar, M & Al-Inany, H (2005). Triggering ovulation for IVF: Letter to the Editor. Reprod Biomed Online 10:142.CrossRefGoogle ScholarPubMed

Aboulghar, MA & Mansour, RT (2003). Ovarian hyperstimulation syndrome: classification and critical analysis of preventive measures. Hum Reprod Update 9:275–89.CrossRefGoogle ScholarPubMed

Aboulghar, MA, Mansour, RT, Serour, GI et al. (1991). The impact of follicular aspiration and luteal phase support on the incidence of ovarian hyperstimulation. Hum Reprod 6(Suppl):174–5.Google Scholar

Aboulghar, MA, Mansour, RT, Serour, GI et al. (1992). Follicular aspiration does not protect against the development of ovarian hyperstimulation syndrome. J Assist Reprod Genet 9:238–43.CrossRefGoogle Scholar

Aboulghar, MA, Mansour, RT, Serour, GI et al. (1996a). Ovarian hyperstimulation syndrome: modern concepts in pathophysiology and management. Middle East Fertil Soc J 1:3–16.Google Scholar

Aboulghar, MA, Mansour, RT, Serour, GI et al. (1996b). Recombinant follicle-stimulating hormone in the treatment of patients with history of severe ovarian hyperstimulation syndrome. Fertil Steril 66:757–60.CrossRefGoogle Scholar

Aboulghar, MA, Mansour, RT, Serour, GI et al. (1997). Oocyte quality in patients with severe ovarian hyperstimulation syndrome. Fertil Steril 68:17–21.CrossRefGoogle ScholarPubMed

Aboulghar, MA, Mansour, RT, Serour, GI et al. (2000). Reduction of human menopausal gonadotrophin dose before coasting prevents severe ovarian hyperstimulation syndrome with minimal cycle cancellation. J Assist Reprod Genet 17:298–301.CrossRefGoogle ScholarPubMed

Aboulghar, M, Evers, JH, Al-Inany, H (2002). Intravenous albumin for preventing severe ovarian hyperstimulation syndrome. Hum Reprod 17:3027–32; and Cochrane Database Syst Rev2:CD001302.CrossRefGoogle ScholarPubMed

Adamson, G, Lancaster, P, Mouzon, J et al. (2005). ICMART world collaborative report on in vitro fertilization 2000. Fertil Steril 84(suppl 1):S107–259.CrossRefGoogle Scholar

Adashi, EY, Rock, JA, Guzick, D et al. (1981). Fertility following bilateral ovarian wedge resection: a critical analysis of 90 consecutive cases of the polycystic ovary syndrome. Fertil Steril 36:320–5.CrossRefGoogle ScholarPubMed

Albano, C, Felberbaum, RE, Smitz, J et al. (2000). Ovarian stimulation with hMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist, cetrorelix and the LHRH-agonist buserelin. Hum Reprod 15:526–31.CrossRefGoogle ScholarPubMed

Al-Inany, H & Aboulghar, M (2002). GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod 17:874–85.CrossRefGoogle ScholarPubMed

Almeida, OD Jr & Rizk, B (1998). Microlaparoscopic ovarian drilling under local anesthesia. Middle East Fertil Soc J 3:189–91.Google Scholar

Al-Shawaf, T, Zosmer, A, Hussain, S et al. (2001). Prevention of severe ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer: a modified ‘coasting’ strategy based on ultrasound for identification of high-risk patients. Hum Reprod 16:24–30.CrossRefGoogle ScholarPubMed

Al-Shawaf, T, Zosmer, A, Tozer, A et al. (2002). Value of measuring serum FSH in addition to serum estradiol in a coasting programme to prevent severe OHSS. Hum Reprod 17:1217–21.CrossRefGoogle Scholar

Amso, NN, Ahuga, KK, Morris, N et al. (1990). The management of predicted OHS involving gonadotrophin-releasing analogue with elective cryopreservation of all pre-embryos. Fertil Steril 53:1087–90.CrossRefGoogle Scholar

Armar, NA & Lachelin, GC (1993). Laparoscopic ovarian diathermy: an effective treatment for antiestrogen resistant anovulatory infertility in women with polycystic ovary syndrome. Br J Obstet Gynaecol 100:161–4.CrossRefGoogle ScholarPubMed

Asch, RH, Ivery, G, Goldsman, M et al. (1993). The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. Hum Reprod 8:1015–20.CrossRefGoogle ScholarPubMed

Awonuga, AO, Pittrof, RF, Zaidi, J et al. (1996). Elective cryopreservation of all embryos in women at risk of developing ovarian hyperstimulation syndrome may not prevent the condition but reduces the live birth rate. J Assist Reprod Genet 13:401–6.CrossRefGoogle ScholarPubMed

Balasch, J, Fabregues, F, Tur, R et al. (1995). Further characterizaion of the luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles. Hum Reprod 10:1377–81.Google Scholar

Balasch, J, Tur, R, Creus, M, Buxaderas, R et al. (1994). Triggering of ovulation by a gonadotrophin releasing hormone agonistin gonadotrophin-stimulated cycles for prevention of ovarian hyperstimulation syndrome and multiple pregnancy. Gynecol Endocrinol 8:7–9.CrossRefGoogle Scholar

Balen, AH (1999). Ovarian hyperstimulation syndrome. Letter to the Editor. Hum Reprod 14:1138.CrossRefGoogle Scholar

Balen, AH & Jacobs, HS (1991). Gonadotropin surge attenuating factor: a missing link in the control of LH secretion?Clin Endocrinol (Oxford) 35:399–402.CrossRefGoogle ScholarPubMed

Balen, AH & Jacobs, HS (1994). Prospective study comparing unilateral and bilateral laparoscopic ovarian diathermy in women with polycystic ovary syndrome. Fertil Steril 62:921–5.CrossRefGoogle ScholarPubMed

Balen, AH, Braat, DD, West, C et al. (1994). Cumulative conception and live birth rates after the treatment of anovulatory infertility: safety and efficacy ovulation induction in 200 patients. Hum Reprod 9:1563–70.CrossRefGoogle ScholarPubMed

Barnes, F, Crombie, A, Gardner, D et al. (1995). Blastocyst development and birth after in vitro maturation of human primary oocytes, intracytoplasmic sperm injection and assisted hatching. Hum Reprod 10:3243–7.CrossRefGoogle ScholarPubMed

Barnes, FL, Kausche, A, Tiglias, J et al. (1996). Production of embryos from in vitro-matured primary human oocytes. Fertil Steril 65:1151–6.CrossRefGoogle ScholarPubMed

Barroso, G, Barrionuevo, M, Rao, P et al. (1999). Vascular endothelial growth factor, nitric oxide, and leptin follicular fluid levels correlate negatively with embryo quality in IVF patients. Fertil Steril 72:1024–6.CrossRefGoogle ScholarPubMed

Bayram, N, Wely, M & Veen, F (2001). Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome (Review). Cochrane Database, Issue 1. The Cochrane Collaboration, Chichester: John Wiley & Sons, Ltd.CrossRefGoogle ScholarPubMed

Belaisch-Allart, J, Balaisch, J, Hazout, A et al. (1988). Selective oocyte retrieval: a new approach to ovarian hyperstimulation. Fertil Steril 50:654–6.CrossRefGoogle ScholarPubMed

Belver, J, Munoz, EA, Ballesteros, A et al. (2003). Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Hum Reprod 18:2283–8.CrossRefGoogle Scholar

Benadiva, CA, Davis, O, Kligman, I et al. (1997). Withholding gonadotropin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome. Fertil Steril 67:724–7.CrossRefGoogle ScholarPubMed

Ben-Chetrit, A, Eldar-Geva, T & Gal, M (2001). The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial. Hum Reprod 16:1880–4.CrossRef

Ben-Nun, I, Shulman, A, Ghetler, Y et al. (1993). The significance of 17 beta estradiol levels in highly responding women during ovulation induction in IVF treatment: its impact and prognostic value with respect to oocyte maturation and treatment outcome. J Assist Reprod Genet 10:213–15.CrossRefGoogle ScholarPubMed

Ben-Rafael, Z, Orvieto, R, Dekel, A et al. (1995). Intravenous albumin and the prevention of severe ovarian hyperstimulation syndrome [comment]. Hum Reprod 10:2750–2.CrossRefGoogle Scholar

Blankstein, J, Shalev, J, Saadon, T et al. (1987). Ovarian hyperstimulation syndrome prediction by number and size of preovulatory follicles. Fertil Steril 47:597–602.CrossRefGoogle Scholar

Bracero, MW, Jurema, MN, Posada, JG et al. (2001). Triggering ovulation with leuprorelide acetate (LA) instead of human chorionic gonadotrophin (hCG) after the use of ganirelix for in-vitro fertilization-embryo transfer (IVF-ET) does not compromise cycle outcome and may prevent ovarian hyperstimulation syndrome. Fertil SterilS-93, Abstract O-245. American Society for Reproductive Medicine 57th Annual Meeting, Orlando, FL, General Program Prize, Abstracts of the scientific oral and poster sessions program supplement.Google Scholar

Buvat, J, Buvat-Herbaut, M, Marcolin, G et al. (1989). Purified follicle stimulating hormone in polycystic ovary syndrome: slow administration is safer and more effective. Fertil Steril 51:553–9.CrossRefGoogle Scholar

Cha, K, Koo, JJ, Choi, DH et al. (1991). Pregnancy after in vitro fertilitzation of human follicular oocytes collected from non stimulated cycles, their culture in vitro and their transfer in a donor oocyte program. Fertil Steril 55:103–20.Google Scholar

Cha, KY & Chian, RC (1998). Maturation in vitro of immature human oocytes for clinical use. Hum Reprod Update 4:103–20.CrossRefGoogle ScholarPubMed

Cha, KY, Han, SY, Chung, HM et al. (2000). Pregnancies and deliveries after in vitro maturation culture followed by in vitro fertilization and embryo transfer without stimulation in women with polycystic ovary syndrome. Fertil Steril 73:978–83.CrossRefGoogle ScholarPubMed

Chang, P, Kenley, S, Burns, T et al. (2001). Recombinant human chorionic gonadotrophin (rhCG) in assisted reproductive technology: results of a clinical trial comparing two doses of rhCG (Ovidrel) to urinary hCG (Profasi) for induction of final follicular maturation in in vitro fertilization embryo transfer. Fertil Steril 76:67–74.CrossRefGoogle ScholarPubMed

Chang, RJ (2004). Polycystic ovary syndrome and hyperandrogenic states. In (Strauss, , Barbieri, , Eds),Yen and Jaffe's Reproductive Endocrinology: Pathophysiology and Clinical Management, 5th edition. Philadelphia: Elsevier & Saunders, Chapter 19, p. 600.Google Scholar

Chen, CD, Wu, MY, Yang, JH et al. (1997). Intravenous albumin does not prevent the development of severe ovarian hypertimulation syndrome. Fertil Steril 68:287–91.CrossRefGoogle ScholarPubMed

Chian, RC & Tan, SL (2002). Maturational and developmental competence of cululus-free immature human oocytes derived from stimulated and intracytoplasmic sperm infection cycles. Reprod Biomed Online 5:125–32.CrossRefGoogle Scholar

Chian, RC, Buckett, WM, Too, LL et al. (1999a). Pregnancies resulting from in vitro matured oocytes retrieved from patients with polycystic ovary syndrome after priming with human chorionic gonadotropin. Fertil Steril 72:639–42.CrossRefGoogle Scholar

Chian, RC, Gulekli, B, Buckett, WM et al. (1999b). Priming with human chorionic gonadotropin before retrieval of immature oocytes in women with infertility due to the polycystic ovary syndrome. New Eng J Med 341:1624–6.CrossRefGoogle Scholar

Chian, RC, Buckett, WM, Tulandi, T et al. (2000). Prospective randomized study of human chorionic gonadotrophin priming before immature oocyte retrieval from unstimulated women with polycystic ovarian syndrome. Hum Reprod 15:165–70.CrossRefGoogle ScholarPubMed

Chian, RC, Gulekli, B, Buckett, WM et al. (2001). Pregnancy and delivery after cryopreservation of zygotes produced by in-vitro matured oocytes retrieved from a woman with polycystic ovarian syndrome. Hum Reprod 16:1700–2.CrossRefGoogle ScholarPubMed

Child, TJ, Abdul-Jalil, AK, Gulekli, B et al. (2000). In vitro maturation and fertilization of oocytes from unstimulated normal ovaries, polycystic ovaries, and women with polycystic ovary syndrome. Fertil Steril 76:936–42.CrossRefGoogle Scholar

Child, TJ, Phillips, SJ, Abdul-Jalil, AK et al. (2002). A comparison of in vitro maturation and in vitro fertilization for women with polycystic ovaries. Obstet Gynecol 100:665–70.Google ScholarPubMed

Christin-Maitre, S & Hughes, JN (2003). A comparative randomized multicentric study comparing the step-up versus the step-down protocol in polycystic ovary syndrome. Hum Reprod 18:1626–31.CrossRefGoogle ScholarPubMed

Costabile, L, Unfer, V, Manna, C et al. (2000). Use of intramuscular progesterone versus intravenous albumin for the prevention of ovarian hyperstimulation syndrome. Gynecol Obstet Invest 50:182–5.CrossRefGoogle ScholarPubMed

D'Angelo, A & Amso, N (2002a). ‘Coasting’ (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 3:CD002811.Google Scholar

D'Angelo, A & Amso, NN (2002b). Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Hum Reprod 17:2787–94.CrossRefGoogle Scholar

Daniell, JF & Miller, W (1989). Polycystic ovaries treated by laparoscopic laser vaporization. Fertil Steril 51:232–6.CrossRefGoogle ScholarPubMed

Dechaud, H, Anahory, T, Aligier, N et al. (2000). Coasting: a response to excessive ovarian stimulation. Gynecol Obstet Fertil 28:115–19.Google ScholarPubMed

DeJonge, D, Macklon, NS & Mannaerts, BMJ et al. (1998). High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization. Hum Reprod 13:573–5.CrossRefGoogle Scholar

Leo, V, Marca, A, Ditto, A et al. (1999). Effects of metformin on gonadotrophin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 72:282–5.CrossRefGoogle Scholar

Delvigne A (2004). Epidemiology and pathophysiology of ovarian hyperstimulation syndrome. In (Gerris, J, Olivennes, F, de Sutter, P, Eds), Assisted Reproductive Technologies: Quality and Safety, New York: Parthenon Publishing, Chapter 12, pp. 149–62.Google Scholar

Delvigne, A & Rozenberg, S (2001). Preventive attitude of physicians to avoid OHSS in IVF patients. Hum Reprod 16:2491–5.CrossRefGoogle ScholarPubMed

Delvigne, A & Rozenberg, S (2002a). A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients. Hum Reprod Update 8:291–6.CrossRefGoogle Scholar

Delvigne, A & Rozenberg, S (2002b). Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 8:559–77.CrossRefGoogle Scholar

Delvigne, A, Demoulin, A, Smitz, J et al. (1993). The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features. Hum Reprod 8:1353–60.CrossRefGoogle ScholarPubMed

Delvigne, A, Carlier, C & Rozenberg, S (2001). Is coasting effective for preventing ovarian hyperstimulation syndrome in patients receiving a gonadotropin-releasing hormone antagonist during an in vitro fertilization cycle?Fertil Steril 76:844–6.CrossRefGoogle ScholarPubMed

Delvigne, A, Manigart, Y, Kostyla et al. (2002). Oocyte quality after coasting for ovarian hyperstimulation syndrome prevention. Hum Reprod. 17 (Abstract book 1, p. 450):153.Google Scholar

Dhont, M, straiten, F, Sutter, P (1998). Prevention of severe ovarian hyperstimulation by coasting. Fertil Steril 70:847–50.CrossRefGoogle ScholarPubMed

Donderwinkel, PF, Schoot, DC, Pache, TD et al. (1993). Luteal function following ovulation induction in polycystic ovary syndrome patients using exogenous gonadotrophins in combination with a gonadotrophin-releasing hormone agonist. Human Reprod 8:2027–32.CrossRefGoogle ScholarPubMed

Driscoll, GL, Tyler, JP, Hangan, JT et al. (2000). A prospective, randomized, controlled, double-blind, double-dummy comparison of recombinant and urinary HCG for inducing oocyte maturation and follicular luteinization in ovarian stimulation. Hum Reprod 15:1305–10.CrossRefGoogle ScholarPubMed

Edwards, R (1965). Maturation in vitro of mouse, sheep, cow, pig, rhesus monkey and human ovarian oocytes. Nature 20:349–51.CrossRefGoogle Scholar

Edwards, R, Bavister, B & Steptoe, P (1969). Early stages of fertilization in vitro of human oocytes matured in vitro. Nature 221:632–5.CrossRefGoogle ScholarPubMed

Egbase, PE, Makhseed, M, Al Sharhan, M et al. (1997). Timed unilateral ovarian follicular aspiration prior to administration of human chorionic gonadotrophin for the prevention of severe ovarian hyperstimulation syndrome in in-vitro fertilization: a prospective randomized study. Hum Reprod 12:2603–6.CrossRefGoogle ScholarPubMed

Egbase, P, Al-Awadi, S, Al-sharhan, M et al. (1998). Unilateral ovarian diathermy prior to successful in-vitro fertilisation: a strategy to prevent ovarian hyperstimulation syndrome?J Obstet Gynaecol 18:171–3.Google Scholar

Egbase, PE, Sharhan, MA & Grudzinskas, JG (1999). Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study. Hum Reprod 14:1421–5.CrossRefGoogle ScholarPubMed

Egbase, PE, Al-Sharhan, M & Grudzinskas, JG (2002). Early coasting in patients with polycystic ovarian syndrome is consistent with good clinical outcome. Hum Reprod 17:1212–16.CrossRefGoogle ScholarPubMed

El-Sheikh, MM, Hussein, M, Fouad, S et al. (2001). Limited ovarian stimulation (LOS) prevents the recurrence of severe forms of ovarian hyperstimulation syndrome in polycystic ovarian disease. Eur J Obstet Gynecol Reprod Biol 94:245–9.CrossRefGoogle ScholarPubMed

Emperaire, JC (2005). Triggering ovulation with LH. Reprod Biomed Online 11:270.CrossRefGoogle ScholarPubMed

Emperaire, JC & Ruffie, A (1991). Triggering ovulation with endogenous luteinizing hormone may prevent ovarian hyperstimulation syndrome. Hum Reprod 6:506–10.CrossRefGoogle Scholar

Emperaire, JC & Edwards, RG (2004). Time to revolutionize the triggering of ovulation. Reprod Biomed Online 9:480–3.CrossRefGoogle ScholarPubMed

Endo, T, Honnma, H, Hayashi, T et al. (2002). Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos. Hum Reprod 17:2548–51.CrossRefGoogle ScholarPubMed

European Orgalutran Study Group (2000). Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulation hormone is effective, safe and convenient: results of a controlled, randomized, multicenter trial. Hum Reprod 15:1490–98.CrossRef

European Recombinant LH Study Group (2001). Recombinant human leuteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotrophin in inducing final follicular maturation and ovulation in in-vitro fertilization procedures: results of a multi-center double blind study. J Clin Endocrinol 86:2607–16.

European-Middle East Orgalutran Study Group (2001). Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 16:644–51.CrossRef

The European Recombinant Human Chorionic Gonadotropin Study Group (2000). Induction of final follicular maturation and early luteinization in women undergoing superovulation for ART–recombinant human chorionic gonadotropin (rhCG; Ovidrel) versus urinary hCG (Profasi). Hum Reprod 15:1446–51.CrossRef

Farquhar, C, Vandederckhove, P & Lilford, R (2001). Laparoscopic “drilling” by diathermy or laser for ovulation induction in anovulatroy polycystic ovary syndrome. Cochrane Database Syst Rev 4:CD001122.CrossRefGoogle Scholar

Fatemi, HM, Platteau, P, Albano, C et al. (2002). Rescue IVF and coasting with the use of a GnRH antagonist after ovulation induction. Reprod Biomed Online 5:273–5.CrossRefGoogle ScholarPubMed

Fauser B & Macklon N (2004). Medical approaches to ovarian stimulation for infertility. In (Strauss, Barbieri, Eds), Reproductive Endocrinology: Physiology, Pathophysiology and Clinical Management, 5th edition. Philadelphia: Elsevier, Chapter 31, pp. 965–1012.

Felberbaum, RE & Diedrich, K (2003). Gonadotrophin-releasing hormone antagonists: will they replace the agonists?Reprod Biomed Online 6:43–53.CrossRefGoogle ScholarPubMed

Felberbaum, RE, Reissmann, T, Kupker, W et al. (1995). Preserved pituitary response under ovarian stimulation with hMG and GnRH antagonists (Cetrorelix) in women with tubal infertility. Eur J Obstet Gynecol Reprod Biol 61:151–5.CrossRefGoogle ScholarPubMed

Ferraretti, AP, Gianaroli, L, Magli, C et al. (1999). Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: efficiency and safety. Hum Reprod 14:1457–60.CrossRefGoogle ScholarPubMed

Ferraretti, AP, Gianaroli, L, Magli, C et al. (2001). Transvaginal ovarian drilling: a new surgical treatment for improving the clinical outcome of assisted reproductive technologies in patients with polycystic ovary syndrome. Fertil Steril 76:812–46.CrossRefGoogle ScholarPubMed

Feste JR (1990). General aspects of CO2 laser laparoscopy. In (Baggish MS, Ed.), Endoscopic Laser Surgery, New York: Elsevier, pp. 67–8.Google Scholar

Fluker, MR, Hooper, WM & Yuzpe, AA (1999). Withholding gonadotrophins (‘coasting’) to minimize the risk of ovarian hyperstimulation during superovulation and in-vitro fertilization-embryo transfer cycles. Fertil Steril 71:294–301.CrossRefGoogle Scholar

Fluker, M, Grifo, J, Leader, A et al. (2001). Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 75:38–45.CrossRefGoogle ScholarPubMed

Forman, RG, rydman, R, Egan, D et al. (1990). Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention. Fertil Steril 53:503–9.Google Scholar

Fountain, S, Rizk, B, Avery, S et al. (1995). An evaluation of the effect of pentoxifylline on sperm function and treatment outcome of male-factor infertility: a preliminary study. J Assist Reprod Genet 12:704–9.CrossRefGoogle ScholarPubMed

Friedman, CI, Schmidt, GE, Chang, FE et al. (1984). Severe ovarian hyperstimulation syndrome following follicular aspiration. Am J Obstet Gynecol 150:436–7.CrossRefGoogle Scholar

Friedman, CI, Seifer, DB, Kennard, EA et al. (1998). Elevated level of follicular fluid vascular endothelial growth factor is a marker of diminished pregnancy potential. Fertil Steril 64:268–72.Google Scholar

Fukaya, T, Murakami, T, Tamura, M et al. (1995). Laser vaporization of the ovarian surface in polycystic ovary disease results in reduced ovarian hyperstimulation and improved pregnancy rates. Am J Obstet Gynecol 173:119–25.CrossRefGoogle ScholarPubMed

Garcia-Velasco, JA, Zuniga, A & Pacheco, A (2004). Coasting acts through downregulation of VEGF gene expression and protein secretion. Hum Reprod 19:1530–8.CrossRefGoogle ScholarPubMed

Gerris, J & Royen, E (2000). Avoiding multiple pregnancies in ART: a plea for single embryo transfer. Hum Reprod 15:1884–8.CrossRefGoogle ScholarPubMed

Gerris, J, Vits, A, Joostens, M et al. (1995). Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU). Hum Reprod 10:56–62.CrossRefGoogle Scholar

Gerris, J, Neubourg, D, Royen, E et al. (2002). Elective single day 3 embryo transfer halves the twinning rate without decrease in the ongoing pregnancy rate of an IVF/ICSI program. Hum Reprod 17:2626–31.CrossRefGoogle Scholar

Gerris, J, Sutter, P, Neuberg, D et al. (2004). A real-life prospective health economic study of elective single embryo transfer versus two-embryo transfer in first IVF/ICSI cycles. Hum Reprod 19:917–23.CrossRefGoogle ScholarPubMed

Gjönnaess, H (1984). Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope. Fertil Steril 41:20–5.CrossRefGoogle ScholarPubMed

Gjönnaess H (1994). Ovarian electrocautery in the treatment of women with the polycystic ovary syndrome (PCOS). Factors affecting the results. Acta Obstet Gynecol Scan 73:407–12.CrossRef

Gjönnaess, H & Norman, N (1987). Endocrine effects of ovarian electrocautery in patients with polycystic ovarian disease. Br J Obstet Gynaecol 94:779–82.CrossRefGoogle ScholarPubMed

Goldberg, JM & Falcone, T, Eds (2000). Atlas of Endoscopic Techniques in Gynecology, Edinburgh: W. B. Saunders, Chapter 13, p. 61.Google Scholar

Gokman, O, Ugur, M, Ekin, M et al. (2001). Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilisation programme: a prospective randomized placebo controlled study. Eur J Obstet Gynecol Reprod Biol 96:187–92.CrossRefGoogle Scholar

Gomez, R, Simon, G, Remohi, J et al. (2001). Vascular endothelial growth factor 121 and 164 isoforms increase vascular permeability in hyperstimulation rats. Fertil Steril 76(Suppl 3):4339–48.CrossRefGoogle Scholar

Gomez, R, Lima, I, Simon, C et al. (2004). Administration of low-dose LH induces ovulation and prevents vascular hyperpermeability and vascular endothelial growth factor expression in superovulated rats. Reproduction 127:483–9.CrossRefGoogle ScholarPubMed

Gonen, Y, Balakier, H, Powell, W et al. (1990). Use of gonadotrophin-releasing hormone agonist to trigger follicular maturation for in-vitro fertilization. J Clin Endocrinol Metab 71:918–22.CrossRefGoogle ScholarPubMed

Grace, J, Rizk, B, Mulekar, M (2005). Coasting decreases ovarian hyperstimulatin syndrome in patients at risk. Is the quality of oocytes, embryos and pregnancy rate the price to pay?Fertil Steril 84(Suppl I)s300: 416.CrossRefGoogle Scholar

Graf, MA, Fischer, R, Naether, OG et al. (1997). Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyethyl starch solution in an in-vitro fertilization programme. Hum Reprod 12:2599–602.CrossRefGoogle Scholar

Grochowski, D, Wolczynski, S, Kuczynski, W et al. (2001). Correctly timed coasting reduces the risk of ovarian hyperstimulation syndrome and gives good cycle outcome in an in vitro fertilization program. Gynecol Endocrinol 15:234–8.CrossRefGoogle Scholar

Gurgan, T, Urman, B, Aksu, T et al. (1992). The effect of short-interval laparoscopic lysis of adhesions on pregnancy rates following Nd-Yag laser photocoagulation of polycystic ovaries. Obstet Gynecol 30:45–7.Google Scholar

Halme, J, Toma, SK & Talbert, LM (1995). A case of severe ovarian hyperstimulation in a healthy oocyte donor. Fertil Steril 64:857–9.CrossRefGoogle Scholar

Hamilton-Fairley, D, Kiddy, D, Watson, H et al. (1991). Low-dose gonadotrophin therapy for induction of ovulation in 100 women with polycystic ovary syndrome. Hum Reprod 6:1095–9.CrossRefGoogle ScholarPubMed

Haning, RVAustin, CWJr, Carlson, IH et al. (1983). Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. Fertil Steril 40:31–6.CrossRefGoogle ScholarPubMed

Hedon, B, Hughes, JN, Emperaire, JC et al. (1998). A comparative prospective study of a chronic low dose versus a conventional ovulation stimulation regimen using recombinant human follicle stimulating hormone in anovulatory women. Hum Reprod 13:2688–92.CrossRefGoogle Scholar

Heylen, SM, Puttemans, PJ & Brosens, IA (1994). Polycystic ovarian disease treated by laparoscopic argon laser capsule drilling: comparison of vaporization versus perforation technique. Hum Reprod 9:1038–42.CrossRefGoogle ScholarPubMed

Hoeger, KM, Kochman, L, Wixom, N et al. (2004). A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 82:421–9.CrossRefGoogle ScholarPubMed

Homburg, R, Armar, NA, Eshel, J et al. (1988). Influence of serum luteinizing hormone concentrations on ovulation, conception and early pregnancy loss in polycystic ovary syndrome. Br Med J 297:1024–6.CrossRefGoogle ScholarPubMed

Homburg, R, Levy, T & Ben-Rafael, Z (1995). A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone in polycystic ovary syndrome: slow administration is safer and more effective. Fertil Steril 63:729–33.CrossRefGoogle Scholar

Hornnes, P, Giroud, D, Howles, C et al. (1993). Recombinant human follicle-stimulating hormone treatment leads to normal follicular growth, estradiol secretion, and pregnancy in a World Health Organization group II anovulatory woman. Fertil Steril 60:724–6.CrossRefGoogle Scholar

Howles, CM (2002). The place of gonadotrophin-releasing hormone antagonists in reproductive medicine. Reprod Biomed Online 4(Suppl 3):64–71.CrossRefGoogle ScholarPubMed

Humaidan, O, Bredkjaer, HE, Bungum, I et al. (2005). GnRH agonist (buserelin) or hCG for ovualtion induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 20:1213–20.CrossRefGoogle ScholarPubMed

Imoedemhe, DAG, Chan, RCW, Signe, AB et al. (1991). A new approach to the management of patients at risk of ovarian hyperstimulation in an in-vitro fertilization program. Hum Reprod 6:1088–91.CrossRefGoogle Scholar

International Recombinant Human Chorionic Gonadotropin Study Group (2001). Induction of ovulation in World Health Organization group II anovulatory women undergoing follicular stimulation with recombinant human follicle-stimulating hormone: a comparison of recombinant human chorionic gonadotropin (rhCG) and urinary hCG. Fertil Steril 75:1111–18.CrossRef

Isaza, V, Garcia-Velasco, JA, Aragones, M et al. (2002). Oocyte and embryo quality after coasting: the experience from oocyte donation. Hum Reprod 17:1737–58.CrossRefGoogle ScholarPubMed

Isik, AZ & Vicdan, K (2001). Combined approach as an effective method in the prevention of severe ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 97:208–12.CrossRefGoogle ScholarPubMed

Isik, AZ, Gokmen, A, Zeyneloglu, HB et al. (1996). Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in vitro fertilisation patients: a prospective randomized and controlled study. Eur J Obstet Gynecol Reprod Biol 70:170–83.CrossRefGoogle ScholarPubMed

Itskovitz, J, Boldes, R, Levron, J et al. (1991). Induction of pre-ovulatory luteinizing hormone surge and prevention of hyperstimulation syndrome by gonadotrophin-releasing hormone agonist. Fertil Steril 56:213–20.CrossRefGoogle Scholar

Itskovitz-Eldor, J, Kol, S & Mannaerts, B (2000). Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod 15:1965–8.CrossRefGoogle ScholarPubMed

Jewelewicz, R, James, SL, Finster, M et al. (1972). Quintuplet gestation after ovulation induction with menopausal gonadotropins and pituitary luteinizing hormone. Obstet Gynecol 40:1–5.Google ScholarPubMed

Keckstein, J, Rossmanith, W, Spatzier, K et al. (1990). The effect of laparoscopic treatment of polycystic ovarian disease by CO2laser or Nd:YAG laser. Surg Endoscopy 4:103–7.CrossRefGoogle ScholarPubMed

Kinget, K, Nijs, M, Cox, AM et al. (2002). A novel approach for patients at risk for ovarian hyperstimulation syndrome: elective transfer of a single zona free blastocyst on day 5. Reprod Biomed Online 4:51–5.CrossRefGoogle ScholarPubMed

Koike, T, Araki, S, Ogawa, S et al. (1999). Does i.v. albumin prevent ovarian hyperstimulation syndrome?Hum Reprod 14:1920.CrossRefGoogle ScholarPubMed

Kolibianakis, EM, Schultze-Morgan, A, Schroer, A et al. (2005). A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 20:2887–92.CrossRefGoogle ScholarPubMed

Konig, E, Bussen, S, Sitterlin, M & Steck, T (1998). Prophylactic intravenous hydroxyethyl starch solution prevents moderate–severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, double-blind and placebo-controlled study. Hum Reprod 13:2421–4.CrossRefGoogle ScholarPubMed

Kovacs GT (1998). Polycystic ovaries, surgical management. In (Sutton, C, Diamond, M, Eds), Endoscopic Surgery for Gynecologists, London: W.B. Saunders, Chapter 23, pp. 233–40.Google Scholar

Kovacs, G, Buckler, H, Bangah, M et al. (1991). Treatment of anovulation due to polycystic ovarian syndrome by laparoscopic ovarian electrocautery. Br J Obstet Gynecol 98:30–5.CrossRefGoogle ScholarPubMed

Kulikowski, M, Wolczynski, S, Kuczynski, W et al. (1995). Use of GnRH analog for induction of the ovulatory surge of gonadotropins in patients at risk of the ovarian hyperstimulation syndrome. Gynecol Endocrinol 9:97–9.CrossRefGoogle ScholarPubMed

Kyono, K, Fukunaga, N, Haigo, K et al. (2002). Successful delivery following cryopreservation of zygotes produced by in vitro matured oocytes retrieved from a woman with polycystic ovarian syndrome-like disease: a case report. J Assisted Reprod Genetics 19:390–3.CrossRefGoogle ScholarPubMed

Lainas, T, Petsas, G, Stavropoulou, G et al. (2002). Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization. Fertil Steril 78:529–33.CrossRefGoogle ScholarPubMed

Lanzone, A, Fulghesu, AM, Apa, R et al. (1989). LH surge induction by GnRH agonist at the time of ovulation. Gynecol Endocrinol 3:213–15.CrossRefGoogle ScholarPubMed

Du, A, Kadoch, IJ, Bourcigaux, N et al. (2005). In vitro oocyte maturation for the treatment of infertility associated with polycystic ovarian syndrome: the French experience. Hum Reprod 20:420–4.Google ScholarPubMed

Lee, C, Tummon, I, Martin, J et al. (1998). Does withholding gonadotrophin administration prevent severe ovarian hyperstimulation syndrome?Hum Reprod 13:1157–8.CrossRefGoogle ScholarPubMed

Levinsohn-Tavor, S, Friedler, M, Schachter, A et al. (2003). Coasting – what is the best formula?Hum Reprod 18:937–40.CrossRefGoogle ScholarPubMed

Lewit, N, Kol, S, Manor, D et al. (1995). The use of GnRH analogues for induction of the pre-ovulatory gonadotrophin surge in assisted reproduction and prevention of the ovarian hyperstimulation syndrome. Gynecol Endocrinol 4(Suppl):13.CrossRefGoogle Scholar

Lewit, N, Kol, S, Ronene, N et al. (1996). Does intravenous administration of human albumin prevent severe ovarian hyperstimulation syndrome?Fertil Steril 66:654--6.CrossRefGoogle ScholarPubMed

Liu, J, Lu, G, Qian, Y et al. (2003). Pregnancies and births achieved from in vitro matured oocytes retrieved from poor responders undergoing stimulation in in vitro fertilization cycles. Fertil Steril 80:447–9.CrossRefGoogle ScholarPubMed

Lin, YH, Hwang, JL, Huang, LW et al. (2003). Combination of PSH priming and hCG priming for in-vitro maturation of human oocytes. Hum Reprod 18:1632–6.CrossRefGoogle Scholar

Lord, JM, Flight, IHK & Norman, RJ (2005). Insulin-sensitizing drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome (Review). In: The Cochrane Library, Chichester: John Wiley & Sons Ltd, Issue 1, pp. 1–90.Google Scholar

Ludwig, M, Felberbaum, RE, Devroey, P et al. (2000). Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide®) in controlled ovarian stimulation for assisted reproduction. Arch Gynecol Obstet 264:29–32.CrossRefGoogle Scholar

Ludwig, M, Katalinic, A & Diedrich, K (2001). Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch Gynecol Obstet. 265:175–82.CrossRefGoogle Scholar

Lukaszuk, J, Liss, B, Orpel, J (2005). New method of ovarian hyperstimulation syndrome prevention. Fertil Steril 84(Suppl 1):S95–232.CrossRefGoogle Scholar

MacDougall, JM, Tan, SL, Balen, AH et al. (1993). A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization and the ovarian hyperstimulation syndrome. Hum Reprod 8:233–7.CrossRefGoogle Scholar

Marci, R, Senn, A, Dessole, S et al. (2001). A low-dose stimulation protocol using highly purified follicle-stimulation hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins. Fertil Steril 75:1131–5.CrossRefGoogle Scholar

Mathur, RS, Akeane, AV, Keay, SD et al. (2000). Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 73:901–7.CrossRefGoogle ScholarPubMed

McNatty, KP, Makris, A, DeGrazia, C et al. (1979). The production of progesterone, androgens and estrogens by granulosa cells, thecal tissue, and stromal tissue from human ovaries in vitro. J Clin Endocrinol Metab 49:687–99.CrossRefGoogle ScholarPubMed

Mikkelsen, A (2004). In vitro maturation of human ova. Int Congr Ser 1266160–6.CrossRefGoogle Scholar

Mikkelsen, AL & Lindenberg, S (2001). Benefit of FSH priming of women with PCOS to the in vitro maturation procedure and the outcome: a randomized prospective study. Reproduction 122:587–92.CrossRefGoogle ScholarPubMed

Mitwally, MFM & Casper, RF (2000). Aromatase inhibition: a novel method of ovulation induction in women with polycystic ovarian syndrome. Reprod Technol 10:244–7.Google Scholar

Mitwally, MFM & Casper, RF (2001). Use of an aromatase inhibitor for induction of ovulation. Fertil Steril 75:305–9.CrossRefGoogle ScholarPubMed

Mitwally, MF, Biljan, M & Casper, RF (2005). Pregnancy outcome after the use of an aromatase inhibitor for ovarian stimulation. Am J Obstet Gynecol 192:381–6.CrossRefGoogle ScholarPubMed

Moreno, L, Diaz, I, Pacheco, A et al. (2004). Extended coasting duration exerts a negative impact on IVF cycle outcome due to premature luteinization. Reprod Biomed Online 9:500–4.CrossRefGoogle ScholarPubMed

Morris, RS, Karande, VC, Dudkiewicz, A et al. (1999). Octreotide is not useful for clomiphene cetrate resistance in patients with polycystic ovary syndrome but may reduce the likelihood of ovarian hyperstimulation syndrome. Fertil Steril 71:452–6.CrossRefGoogle Scholar

Mukherjee, T, Copperman, AB, Sandler, B et al. (1995). Severe ovarian hyperstimulation despite prophylactic albumin at the time of oocyte retrieval for in-vitro fertilization and embryo transfer. Fertil Steril 64:641–3.CrossRefGoogle ScholarPubMed

Naether, OGJI & Fischer, R (1993). Adhesion formation after laparoscopic electrocoagulation of the ovarian surface in polycystic ovary patients. Fertil Steril 60:95–8.CrossRefGoogle ScholarPubMed

Nagele, F, Sator, MO, Juza, J et al. (2002). Successful pregnancy resulting from in-vitro matured oocytes retrieved at laparoscopic surgery in a patient with polycystic ovary syndrome: case report. Hum Reprod 17:373–4.CrossRefGoogle Scholar

Ndukwe, G, Thornton, S, Fishel, S et al. (1997). Severe ovarian hyperstimulation syndrome: is it really preventable by prophylactic intravenous albumin?Fertil Steril 68:851–4.CrossRefGoogle ScholarPubMed

Ng, E, Leader, A, Claman, P et al. (1995). Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome in an in-vitro fertilization programme. Hum Reprod 10:107–10.CrossRefGoogle ScholarPubMed

Ohata, Y, Harada, T, Ito, M et al. (2000). Coasting may reduce the severity of the ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome. Gynecol Obstet Invest 50:186–8.CrossRefGoogle ScholarPubMed

Olivennes, F, Fanchin, R, Bouchard, P et al. (1996). Triggering of ovulation by a gonadotrophin-releasing hormone (GnRH) agonist in patients pretreated with GnRH antagonist. Fertil Steril 66:151–3.CrossRefGoogle ScholarPubMed

Olivennes, F, Belaisch-Allart, J, Emeraire, JC et al. (2000). Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (Cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 73:314–20.CrossRefGoogle Scholar

Olivennes, F, Fanchin, R, Bertrand, C et al. (2001). GnRH antagonist in single dose applications. Infertility and Reproductive Medicine Clinics of North America 12:119–28.Google Scholar

Orvieto, R & Ben-Rafael, Z (1996). Prophylactic intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome. Hum Reprod 11:460–1.CrossRefGoogle ScholarPubMed

Orvieto, R, Dekel, A, Dicker, D et al. (1995). A severe case of ovarian hyperstimulation syndrome despite the prophylactic administration of intravenous albumin. Fertil Steril 64:860–2.CrossRefGoogle ScholarPubMed

Ostrzenski, A (1992). Endoscopic carbon dioxide laser ovarian wedge resection in resistant polycystic ovarian disease. Int J Fertil 37:295–9.Google ScholarPubMed

Panay, N, Iammarrone, E, Zosmer, A et al. (1999). Does the prophylactic use of intravenous albumin prevent ovarian hyperstimulation syndrome? A randomized prospective study. Hum Reprod 14:105.CrossRefGoogle Scholar

Parsanezhad, ME, Alborzi, S, Pakniat, M et al. (2003). A double-blind, randomized, placebo-controlled study to assess the efficacy of ketoconazole for reducing the risk of ovarian hyperstimulation syndrome. Fertil Steril 80:1151–5.CrossRefGoogle ScholarPubMed

Pasetto, N & Montanino, G (1964). Induction of ovulation by human gonadotrophins. Acta Endocrinologica 47:1–9.Google ScholarPubMed

Pattinson, HA, Hignett, M, Dunphy, BC et al. (1994). Outcome of thaw embryo transfer after cryopreservation of all embryos in patients at risk of ovarian hyperstimulation syndrome. Fertil Steril 62:1192–6.CrossRefGoogle ScholarPubMed

Penarrubia, J, Balasch, J, Fabregues, F et al. (1998). Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles. Hum Reprod 13:3315–8.CrossRefGoogle ScholarPubMed

Penzias, AL (2002). Luteal phase support. Fertil Steril 77:318–23.CrossRefGoogle ScholarPubMed

Polson, DW, Mason, HD, Saldahna, MB et al. (1987). Ovulation of a single dominant follicle during treatment with low dose pulsatile follicle stimulation hormone in women with polycystic ovary syndrome. Clin Endocrinol (Oxford) 26:205–12.CrossRefGoogle Scholar

Pritts, EA & Atwood, AK (2002). Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod 147:2287–99.CrossRefGoogle Scholar

Queenan JT, Jr, Veeck, LL, Toner, JP et al. (1997). Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but chances of pregnancy are excellent with subsequent frozen-thaw transfers. Hum Reprod 12:1573–6.CrossRefGoogle Scholar

Rabau, E, Serr, DM, David, A et al. (1967). Human menopausal gonadotrophin for anovulation and sterility. Am J Obstet Gynecol 98:92–8.CrossRefGoogle Scholar

Rabinovici, J, Kushnir, O, Shalev, J et al. (1987). Rescue of menotropin cycles prone to develop ovarian hyperstimulation. Br J Obstet Gynecol 94:1098–102.CrossRefGoogle ScholarPubMed

Rabinowitz, R, Laufer, N, Lewin, A et al. (1987). Rate of ovarian hyperstimulation syndrome after high dose hMG for the induction of ovulation in IVF cycles. Hum Reprod 2(Suppl 1)(Abst 63):48.Google Scholar

Ragni, G, Vegetti, W, Riccaboni, A et al. (2005). Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Hum Reprod 20:2421–5.CrossRefGoogle ScholarPubMed

Revel A & Casper RF (2001). The use of LHRH agonists to induce ovulation. In (Devroey, P, Ed.), Infertility and Reproductive Medicine Clinics of North America: GnRH Analogues. Philadelphia: W.B. Saunders and Company, pp. 105–18.Google Scholar

Rimington, MR, Walker, SM & Shaw, RW (1997). The use of laparoscopic ovarian electrocautery in preventing cancellation of in-vitro fertilization treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries. Hum Reprod 12:1443–7.CrossRefGoogle ScholarPubMed

Risquez, F, Pennehouat, G, Fernandez, R et al. (1993). Microlaparoscopy: a preliminary report. Hum Reprod 8:1701–5.CrossRefGoogle ScholarPubMed

Rizk B (1992). Ovarian hyperstimulation syndrome. In (Brinsden, PR, Rainsbury, PA, Eds), A Textbook of in Vitro Fertilization and Assisted Reproduction. Carnforth, UK: Parthenon Publishing, Chapter 23, pp. 369–84.Google Scholar

Rizk B (1993a). Ovarian hyperstimulation syndrome. In (Studd, J, Ed.), Progress in Obstetrics and Gynecology, Volume 11. Edinburgh: Churchill Livingtone, Chapter 18, pp. 311–49.Google Scholar

Rizk B (1993b). Prevention of ovarian hyperstimulation syndrome: the Ten Commandments. Presented at the European Society of Human Reproduction and Embryology Symposium, Tel Aviv, Israel, 1–2.

Rizk B (2001). Ovarian hyperstimulation syndrome: prediction, prevention and management. In (Rizk, B, Devroey, P, Meldrum, DR, Eds), Advances and Controversies in Ovulation Induction. 34th ASRM Annual Postgraduate Program, Middle East Fertility Society Precongress Course. ASRM, 57th Annual Meeting, Orlando, FL, Birmingham, Alabama: the American Society for Reproductive Medicine, pp. 23–46.Google Scholar

Rizk B (2002). Can OHSS in ART be eliminated? In (Rizk, B, Meldrum, D, Schoolcraft, W, Eds), A Clinical Step-by-Step Course for Assisted Reproductive Technologies. 35th ASRM Annual Postgraduate Program, Middle East Fertility Society Precongress Course. ASRM, 58th Annual Meeting, Seattle, WA, Birmingham, Alabama: The American Society for Reproductive Medicine, pp. 65–102.Google Scholar

Rizk B (in press). The role of coasting in the prevention of threatening OHSS: an American perspective. In (Gerris, J, Olivennes, F, Delvigne, A, Eds), Ovarian Hyperstimulation Syndrome. London: Taylor and Francis.

Rizk, B & Aboulghar, M (1991). Modern management of ovarian hyperstimulation syndrome. Hum Reprod 6:1082–7.CrossRefGoogle ScholarPubMed

Rizk B & Abdalla H (2006). Ovulatory dysfunction and ovulation induction. In (Rizk, B, Abdalla, H, Eds), Infertility and assisted reproduction. Oxford, UK: Health Press, Chapter I.4, pp. 39–59.Google Scholar

Rizk B & Aboulghar MA (2005). Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In (Brinsden, P, Ed.), A Textbook of In-vitro Fertilization and Assisted Reproduction. London: Parthenon, Chapter 12, pp. 217–58.CrossRefGoogle Scholar

Rizk B & Nawar MG (2001). Laparoscopic ovarian drilling for surgical induction of ovulation in polycystic ovarian syndrome. In (Allahbadia, G, Ed.), Manual of Ovulation Induction. Mumbai, India: Rotunda Medical Technologies, Chapter 18, pp. 140–4.Google Scholar

Rizk B & Nawar MG (2004). Ovarian hyperstimulation syndrome. In (Serhal, P, , Overton C, Eds), Good Clinical Practice in Assisted Reproduction. Cambridge, UK: Cambridge University Press, Chapter 8, pp. 146–66.CrossRefGoogle Scholar

Rizk, B & Smitz, J (1992). Ovarian hyperstimulation syndrome after superovulation for IVF and related procedures. Hum Reprod 7:320–7.CrossRefGoogle ScholarPubMed

Rizk, B & Thorneycroft IH (1996). Does recombinant follicle stimulating hormone abolish the risk of severe ovarian hyperstimulation syndrome?Fertil Steril 65:S151–2.Google Scholar

Rizk, B, Aboulghar, MA, Mansour, RT et al. (1991a). Severe ovarian hyperstimulation syndrome: analytical study of twenty-one cases. Hum Reprod 6:S368–9.Google Scholar

Rizk, B, Vere M, Martin R et al. (1991b). Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/HMG super-ovulation for in-vitro fertilization. Hum Reprod 6:S368.

Rizk, B, Tan, SL, Morcos, S et al. (1991c). Heterotopic pregnancies after in-vitro fertilizations and embryo transfer. Am J Obstet Gynecol 164:161–4.CrossRefGoogle Scholar

Rizk, B, Fountain, S, Avery, S et al. (1995). Successful use of pentoxifylline in male-factor infertility and previous failure of in vitro fertilization: a prospective randomized study. J Assist Reprod Genet 12:710–14.CrossRefGoogle ScholarPubMed

Rizk, B, Aboulghar, MA, Smitz, J et al. (1997). The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update 3:255–66.CrossRefGoogle ScholarPubMed

Romeu, A, Monzo, A, Peiro, T et al. (1997). Endogenous LH surge versus hCG as ovulation trigger after low-dose highly purified FSH in IUI: a comparison of 761 cycles. J Assist Reprod Genet 14:518–24.CrossRefGoogle ScholarPubMed

Rongieres-Bertrand, C, Olivennes, F, Gighini, C et al. (1999). Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Hum Reprod 14:683–8.CrossRefGoogle ScholarPubMed

Rosenwaks, Z (2003). Ovarian hyperstimulation syndrome (OHSS): strategies for prevention. In (Muasher SJ, Rizk B, Eds), American Society for Reproductive Medicine 59th Ann Mtg. 36th Annual Post Graduate Program. San Antonio, Texas: Published by the American Society for Reproductive Medicine, Birmingham, AL, pp. 153–73.Google Scholar

Salat-Baroux, J, Alvarez, S, Antoine, JM et al. (1990). Treatment of hyperstimulation during in-vitro fertilization. Hum Reprod 5:36–9.CrossRefGoogle ScholarPubMed

Schenker, JG & Weinstein, D (1978). Ovarian hyperstimulation syndrome: a current survey. Fertil Steril 30:255–68.Google ScholarPubMed

Schmidt-Sarosi, C, Kaplan, DR, Sarosi, P et al. (1995). Ovulation triggering in clomiphene citrate-stimulated cycles: human chorionic gonadotrophin versus a gonadotrophin releasing hormone agonist. J Assist Reprod Genet 12:167–74.CrossRefGoogle Scholar

Schwarzler, P, Abendstein, BJ, Klingler, A et al. (2003). Prevention of severe ovarian hyperstimulation syndrome (OHSS) IVF patients by steroidal ovarian suppression – a prospective randomized study. Hum Fertil 6:125–9.CrossRefGoogle ScholarPubMed

Scott, RT, Bailey, SA, Kost, ER et al. (1994). Comparison of leuprolide acetate and human chorionic gonadotrophin for the induction of ovulation in clomiphene citrate-stimulated cycles. Fertil Steril 61:872–4.CrossRefGoogle ScholarPubMed

Segal, S & Casper, RF (1992). Gonadotrophin-releasing hormone agonist versus human chorionic gonadotrophin for triggering follicular maturation in in-vitro fertilization. Fertil Steril 57:1254–8.CrossRefGoogle ScholarPubMed

Seibel, MM, Kamrava, MM, McArdle, C et al. (1984). Treatment of polycystic ovarian disease with chronic low dose follicle stimulating hormone: biochemical changes and ultrasound correlation. Int J Fertil 29:39–43.Google ScholarPubMed

Serin, IS, Ozcelik, B, Bekyurek, T et al. (2002). Effects of pentoxifylline in the prevention of ovarian hyperstimulation syndrome in a rabbit model. Gynecol Encocrinol 5:355–9.CrossRefGoogle Scholar

Shahata, M, Yang, D, al-Natsha, SD et al. (1994). Intravenous albumin and severe ovarian hyperstimulation. Hum Reprod 9:2186.CrossRefGoogle ScholarPubMed

Shaker, AG, Zosmer, A, Dean, N et al. (1996). Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome. Fertil Steril 65:992–6.CrossRefGoogle ScholarPubMed

Shalev, E, Geslevich, Y & Ben-Ami, M (1994). Induction of pre-ovulatory luteinizing hormone surge by gonadotrophin-releasing hormone agonist for women at risk for developing the ovarian hyperstimulation syndrome. Hum Reprod 9:417–19.CrossRefGoogle ScholarPubMed

Shalev, E, Geslevich, Y, Matilsky, M et al. (1995a). Gonadotrophin-releasing hormone agonist compared with human chorionic gonadotrophin for ovulation induction after clomiphene citrate treatment. Hum Reprod 10:2541–4.CrossRefGoogle Scholar

Shalev, E, Geslevich, Y, Matilsky, M et al. (1995b). Induction of pre-ovulatory gonadotrophin surge with gonadotrophin-releasing hormone agonist compared to pre-ovulatory injection of human chorionic gonadotrophins for ovulation induction in intrauterine insemination. Hum Reprod 10:2244–7.CrossRefGoogle Scholar

Shalev, E, Giladi, Y, Matilsky, M et al. (1995c). Decreased incidence of severe ovarian hyperstimulation syndrome in high risk in-vitro fertilization patients receiving intravenous albumin: a prospective study. Hum Reprod 10:1373–6.CrossRefGoogle Scholar

Sher, G, Salem, R, Feinman, M et al. (1993). Eliminating the risks of life-endangering complications following over-stimulation with menotropin fertility agents: a report on women undergoing in-vitro fertilization and embryo transfer. Obstet Gynecol 81:1009–11.Google Scholar

Sher, G, Zouves, C, Feinman, M et al. (1995). Prolonged coasting: an effective method. Hum Reprod 10:3107–9.CrossRefGoogle ScholarPubMed

Shoham, Z, Patel, A & Jacobs, HS (1991). Polycystic ovarian syndrome: safety and effectiveness of stepwise and low-dose administration of purified follicle-stimulating hormone. Fertil Steril 55:1051–6.CrossRefGoogle ScholarPubMed

Shoham, Z, Weissman, A, Barash, A et al. (1994). Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo controlled study. Fertil Steril 62:137–42.CrossRefGoogle Scholar

Smitz, J, Gerard, P, Camus, M et al. (1992). Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and hMG in a desensitization or flare-up protocol. Hum Reprod 7:1225–9.CrossRefGoogle ScholarPubMed

Soliman, S, Daya, S, Collins, J et al. (1994). The role of luteal phase support in infertility treatment: a meta-analysis of randomized trials. Fertil Steril 61:1068–76.CrossRefGoogle ScholarPubMed

Son, WY, Yoon, SH, Park, SJ et al. (2002). Ongoing twin pregnancy after virification of blastocysts produced by in-vitro matured oocytes retrieved from a woman with polycystic ovary syndrome: case report. Hum Reprod 17:2963–6.CrossRefGoogle ScholarPubMed

Stein, FI (1964). Duration of fertility following ovarian wedge resection – Stein–Leventhal syndrome. Western J Surg, Obstet Gynecol 78:237–40.Google Scholar

Stein, FI & Leventhal, ML (1935). Amenorrhea associated with bilateral polycystic ovaries. Am J Obst Gynecol 29:181–91.CrossRefGoogle Scholar

Tan, SL & Child, TJ (2002). In-vitro maturation of oocytes from unstimulated polycystic ovaries. Reprod Biomed Online 4:18–23.CrossRefGoogle ScholarPubMed

Tan SL, Balen A, El Hussein E et al. (1992). The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in-vitro fertilization: a prospective randomized study. Fertil Steril 58:378–83.CrossRef

Tomazevic, T & Meden-Vrtovec, H (1996). J Assist Reprod Genet 13:282–6.CrossRef

Tortoriello, DV, McGovern, PG, Colon, JM et al. (1998a). ‘Coasting’ does not adversely affect cycle outcome in a subset or highly responsive in-vitro fertilization patients. Fertil Steril 69:454–60.CrossRefGoogle Scholar

Tortoriello, DV, McGovern, PG, Colon, JM et al. (1998b). Critical ovarian hyperstimulation syndrome in coasted in-vitro fertilization patients. Hum Reprod 13:3005–8.CrossRefGoogle Scholar

Tozer, AJ, Al-Shawaf, T, Zosmer, A et al. (2001). Does laparoscopic ovarian diathermy affect the outcome of IVF-embryo transfer in women with polycystic ovarian syndrome: a retrospective comparative study. Hum Reprod 16:91–5.CrossRefGoogle ScholarPubMed

Tozer, AJ, Iles, RK, Iammarrone, E et al. (2004a). Characteristics of populations of granulosa cells from individual follicles in women undergoing ‘coasting’ during controlled ovarian stimulation (COS) for IVF. Hum Reprod 19:2561–8.CrossRefGoogle Scholar

Tozer, AJ, Iles, RK, Iammarrone, E et al. (2004b). The effects of ‘coasting’ on follicular fluid concentrations of vascular endothelial growth factor in women at risk of developing ovarian hyperstimulation syndrome. Hum Reprod 19:522–8.CrossRefGoogle Scholar

Trounson, A, Wood, C & Kausche, A (1994). In vitro maturation and the fertilization and developmental competence of oocytes recovered from untreated polycystic ovarian patients. Fertil Steril 62:353–62.CrossRefGoogle ScholarPubMed

Tulchinsky, D, Nash, H, Brown, K et al. (1991). A pilot study of the use of gonadotrophin-releasing hormone analog for triggering ovulation. Fertil Steril 55:644–6.CrossRefGoogle ScholarPubMed

Tütinen, A, Husa, LM, Tulppala, M et al. (1995). The effect of cryopreservation in prevention of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol 102:326–9.CrossRefGoogle Scholar

Ulug, U, Bahceci, M, Erden, HF et al. (2002). The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. Hum Reprod 17:310–13.CrossRefGoogle ScholarPubMed

Urman, B, Pride, SM & Ho Yuen, B (1992). Management of over-stimulated gonadotrophin cycles with a controlled drift period. Hum Reprod 7:213–17.CrossRefGoogle Scholar

Blerkom, J, Antczak, M & Schrader, R (1997). The developmental potential of the human oocyte is related to the dissolved oxygen content of follicular fluid: association with vascular endothelial growth factor levels and perifollicular blood flow characteristics. Hum Reprod 12:1047–55.CrossRefGoogle ScholarPubMed

Vande Wiele, RL, Bogumil, J, Dyrenfurth, I et al. (1970). Mechanisms regulating the menstrual cycle in women. Hormone Res 26:63–103.Google ScholarPubMed

Meer, S, Gerris, J, Joostens, M et al. (1993). Triggering of ovulation using a gonadotrophin-releasing hormone agonist does not prevent ovarian hyperstimulation syndrome. Hum Reprod 8:1628–31.CrossRefGoogle Scholar

Santbrink, EJ & Fauser, BC (1997). Urinary follicle-stimulating hormone for normogonadotropic clomiphene-resistant anovulatory infertility: prospective, randomized comparison between low-dose step-up and step-down regimen. J Clin Endocrinol Metab 82:3597–602.Google Scholar

Santbrink, EJ, Donderwinkel, PF, Dessel, TJ et al. (1995). Gonadotrophin induction of ovulation using a step-down dose regimen: single-centre clinical experience in 82 patients. Hum Reprod 10:1043–53.Google ScholarPubMed

Veek, L, Wothman, J, Witmyer, J et al. (1983). Maturation and fertilization of morphologically immature human oocytes in a program of in vitro fertilization. Fertil Steril 39:694–6.Google Scholar

Verhelst, J, Gerris, J, Joostens, M et al. (1993). Clinical and endocrine effects of laser vaporization in patients with polycystic ovarian disease. Gynecol Endocrinol 7:49–55.CrossRefGoogle ScholarPubMed

Wada, I, Matson, PI, Burslem, RM et al. (1991). Ovarian hyperstimulation syndrome in GnRH/Hmg stimulated cycles for IVF or GIFT. J Obstet Gynecol 11:88–9.Google Scholar

Wada, I, Matson, PL, Troup, SA et al. (1992a). Outcome of treatment subsequent to the elective cryopreservation of all embryos from women at risk of developing the ovarian hyperstimulation syndrome. Hum Reprod 7:962–6.CrossRefGoogle Scholar

Wada, I, Matson, PL, Horne G et al. (1992b). Is continuation of a gonadotrophin releasing hormone agonist (GnRH-a) necessary for women at risk of developing ovarian hyperstimulation syndrome?Hum Reprod 7:1090–3.CrossRefGoogle Scholar

Wada, I, Matson, PL, Troup, SA et al. (1993a). Does elective cryopreservation of all embryos from women at risk of ovarian hyperstimulation syndrome reduce the incidence of the condition?Br J Obstet Gynaecol 10:265–9.CrossRefGoogle Scholar

Wada, I, Matson, PL, Horne, G et al. (1993b). Assisted conception using buserelin and human menopausal gonadotrophins in women with polycystic ovary syndrome. Br J Obstet Gynaecol 100:365–9.CrossRefGoogle Scholar

Waldenstrom, U, Kahn, J, Marsk, L et al. (1999). High pregnancy rates and successful prevention of severe ovarian hyperstimulation syndrome by ‘prolonged coasting’ of very hyperstimulated patients: a multi-centre study. Hum Reprod 14:294–7.CrossRefGoogle Scholar

Yovich, JL (1993). Pentoxyfylline: actions and applications in assisted reproduction. Hum Reprod 8:1786–91.CrossRefGoogle ScholarPubMed

Zelinski-Wooten, MB, Lanzendorf, SE, Wolf, et al. (1991). Titrating luteinizing hormone surge requirements for ovulatory changes in the primate follicle. I. Oocyte maturation and corpus luteum function. J Clin Endocrin Metab 73:577–83.CrossRefGoogle ScholarPubMed